Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V6VD
|
|||
| Drug Name |
Anti-CD20-CAR vector-transduced autologous T cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Phase 1/2 | [1] | |
| B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00; ICD-9: 204.1] | Phase 1/2 | [1] | ||
| Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 1/2 | [1] | ||
| Follicular lymphoma [ICD-11: 2A80; ICD-9: 202] | Phase 1/2 | [1] | ||
| Haematopoietic/lymphoid cancer [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1/2 | [1] | ||
| Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1] | Phase 1/2 | [1] | ||
| Prolymphocytic leukaemia [ICD-11: 2A82.1; ICD-10: C91.3] | Phase 1/2 | [1] | ||
| Company |
Chinese PLA General Hospital
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | CAR-T-Cell-Therapy | [1] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01735604) Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.